
news report
NCI Offers Checkpoint-Resistant Cancer Cell Line for Licensing
The CRISPR-engineered mouse colon-cancer model removes B2m and MHC-I antigen presentation to support preclinical research on resistance to PD-1 and PD-L1 therapies.
entities

news report
The CRISPR-engineered mouse colon-cancer model removes B2m and MHC-I antigen presentation to support preclinical research on resistance to PD-1 and PD-L1 therapies.

news report
The international HCMI resource links 665 patient-derived laboratory models with molecular and clinical data for precision-oncology research.

news report
The prototype platform uses 16,567 CNS reference profiles across 133 diagnostic classes and includes separate kidney-tumor work; commercialization and regulated deployment remain prospective.

news report
The international resource links patient-derived organoids and other models with molecular and clinical data, including rare cancers and donors of non-European ancestry.

news report
The SenNet papers introduce 'senotypes' to distinguish rare cells by tissue and condition, a step toward studying harmful and beneficial roles without treating them as one group.